Lichen-forming fungi: potential sources of novel metabolites.

The challenge for today's pharmaceutical industry lies in the discovery and development of new, pharmacologically active molecules. Metabolites produced by microorganisms, and fungi in particular, are a resource for which the therapeutic potential has been recognized, but one that remains largely unexplored and unexploited. Approximately 20% of all known fungal species are obligate symbionts in lichens; this major group of fungi has been long neglected by mycologists, and overlooked by industry.